RxDoctor Payments Data

Balaji Ayyar

Gastroenterology · San Antonio, TXNPI 1437595204

Payments from drug & device makers

$2,890in general payments, 2019–2025

Across 143 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$541
  • Gilead$239
  • Lilly USA, LLC$217
  • Phathom Pharmaceuticals, Inc.$212
  • Celltrion USA Inc.$139
  • plus $510 from 11 others

What the payments were for

  • Food & beverage$2,890100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,890 in reported general payments places this provider in the 45th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$202,858
Medicare patients
423
Services billed
6,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide42$30,252
Dexlansoprazole DrDexlansoprazole38$8,368
Mesalamine15$7,453
ClenpiqSod Picosulf/Mag Ox/Citric Ac28$4,753
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C34$4,667
Omeprazole220$3,060
Esomeprazole Magnesium71$2,830
Pantoprazole Sodium103$1,655
Cholestyramine LightCholestyramine15$1,586
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag13$1,573
Colestipol Hcl22$1,219
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl52$897
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl48$791
Colesevelam Hcl11$762
Rabeprazole Sodium24$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,032$30,25242 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$130$4,66734 claims
Braintree Laboratories, Inc.Suflave$38$1,57313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →